ArticleFrontiers in pharmacology2025
Evaluating the efficacy of different doses of tocilizumab in treating critically ill COVID-19 patients: a single-center retrospective cohort study.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A nomogram based on LASSO-logistic regression for predicting tocilizumab-associated hypofibrinogenemia in patients with rheumatic diseases.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To evaluate the therapeutic efficacy of different doses of tocilizumab (TCZ) in patients with severe or critical COVID-19. Methods: In this single-center retrospective cohort study conducted from January 2023 to January 2024, 56 hospitalized patients with severe or critical COVID-19 who received TCZ were included. Patients were categorized into three groups based on the number of TCZ doses administered: one dose (n = 16), two doses (n = 32), and three doses (n = 8). The primary outcomes were in-hospital mortality and 30-day mortality following the first dose. Secondary outcomes included changes in inflammatory marker levels, length of hospital stay, duration of mechanical ventilation, and incidence of complications during hospitalization. Results: After adjusting for potential confounders, there were no statistically significant differences in 30-day mortality (one dose vs. two doses HR 0.39; 95% CI, 0.15-1.04; P = 0.060 and one dose vs. three doses HR 0.27; 95% CI, 0.06-1.07; P = 0.067) or in-hospital mortality (one dose vs. two doses HR 0.65; 95% CI, 0.35-1.25; P = 0.090 and one dose vs. three doses HR 0.70; 95% CI, 0.40-1.50; P = 0.300) among the three groups. However, all groups showed a favorable response in inflammatory markers. Interleukin-6 (IL-6) levels initially increased after TCZ administration but subsequently declined in a fluctuating pattern. C-reactive protein (CRP) levels decreased consistently across all groups, while procalcitonin showed a modest decline. The number of TCZ doses had no significant impact on length of hospital stay, duration of mechanical ventilation, or the incidence of complications such as respiratory failure requiring mechanical ventilation, heart failure, secondary infections, thrombotic/embolic events, transaminase elevation, neutropenia, GI perforation/Haemorrhage, or acute kidney injury. Conclusion: Administering additional doses of TCZ beyond the initial dose was not associated with further reductions in mortality or improvements in other major clinical outcomes in patients with severe or critical COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.